X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (83) 83
Patent (41) 41
Conference Proceeding (15) 15
Publication (13) 13
Book Review (9) 9
Book / eBook (2) 2
Magazine Article (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (46) 46
human necessities (41) 41
hygiene (41) 41
medical or veterinary science (41) 41
preparations for medical, dental, or toilet purposes (41) 41
chemistry (39) 39
general tagging of cross-sectional technologies spanning over several sections of the ipc (39) 39
general tagging of new technological developments (39) 39
investigating or analysing materials by determining theirchemical or physical properties (39) 39
measuring (39) 39
metallurgy (39) 39
organic chemistry (39) 39
peptides (39) 39
physics (39) 39
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (39) 39
technologies for adaptation to climate change (39) 39
technologies or applications for mitigation or adaptation againstclimate change (39) 39
testing (39) 39
oncology (32) 32
animals (28) 28
mice (26) 26
humans (25) 25
immunotherapy (21) 21
abridged index medicus (19) 19
immunology (19) 19
cancer (13) 13
male (13) 13
female (12) 12
in-vivo (12) 12
mice, inbred balb c (11) 11
interferon-gamma (10) 10
melanoma (10) 10
natural-killer-cells (10) 10
care and treatment (9) 9
interleukin-2 - administration & dosage (9) 9
mice, inbred c57bl (9) 9
t-cells (9) 9
apoptosis (8) 8
article (8) 8
cytokine (8) 8
expression (8) 8
interleukin-12 - administration & dosage (8) 8
medicine, research & experimental (8) 8
neoplasm transplantation (8) 8
research (8) 8
adult (7) 7
antineoplastic agents - therapeutic use (7) 7
interferon-gamma - physiology (7) 7
interleukin-12 - therapeutic use (7) 7
killer cells, natural - immunology (7) 7
mice, knockout (7) 7
antibodies, monoclonal - therapeutic use (6) 6
cell line, tumor (6) 6
cell stimulatory factor (6) 6
health aspects (6) 6
il-12 (6) 6
neoplasms - drug therapy (6) 6
neuroblastoma - drug therapy (6) 6
tumors (6) 6
antineoplastic agents - administration & dosage (5) 5
antineoplastic agents - pharmacology (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
apoptosis - drug effects (5) 5
blockade (5) 5
carcinoma, renal cell - drug therapy (5) 5
drug synergism (5) 5
guidelines (5) 5
ifn-gamma (5) 5
injections, intraperitoneal (5) 5
interferon-gamma - biosynthesis (5) 5
interleukin-12 - pharmacology (5) 5
ligands (5) 5
melanoma - drug therapy (5) 5
metastatic melanoma (5) 5
mice, scid (5) 5
middle aged (5) 5
neoplasms - therapy (5) 5
patients (5) 5
t-lymphocytes - immunology (5) 5
therapy (5) 5
tumor cells, cultured (5) 5
aged (4) 4
antibodies, monoclonal - adverse effects (4) 4
antineoplastic agents - adverse effects (4) 4
antitumor activity (4) 4
apoptosis - immunology (4) 4
b7 family (4) 4
biomarkers (4) 4
cytokines (4) 4
dose-response relationship (4) 4
drug therapy (4) 4
fas ligand protein (4) 4
fas receptor - physiology (4) 4
interferon-gamma - genetics (4) 4
interleukin-12 (4) 4
interleukin-2 - therapeutic use (4) 4
ipilimumab (4) 4
lymphocyte maturation factor (4) 4
medicine, general & internal (4) 4
neoplasm metastasis (4) 4
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2455 - 2465
Antibodies to PD-1 protein and to one of its ligands, PD-L1, have shown antitumor activity. Unleashing T cells from inhibitory signals may be a strategy to... 
MEDICINE, GENERAL & INTERNAL | LYMPHOCYTE-ASSOCIATED ANTIGEN-4 | SOLID TUMORS | RESPONSE CRITERIA | CELL ACTIVATION | IMMUNOTHERAPY | B7 FAMILY | ANTITUMOR IMMUNITY | CLINICAL ACTIVITY | PHASE-I | T-CELLS | Neoplasms - metabolism | Humans | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Dose-Response Relationship, Drug | Pancreatic Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Adult | Female | Carcinoma, Renal Cell - drug therapy | Ovarian Neoplasms - drug therapy | Programmed Cell Death 1 Receptor - metabolism | Stomach Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Neoplasms - drug therapy | Antibodies, Monoclonal - administration & dosage | Melanoma - drug therapy | Nivolumab | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Intravenous administration | Kidneys | Immune response | Disease | PD-1 protein | Tumor cells | Lung | Colorectal carcinoma | Body weight | Melanoma | Lymphocytes T | Breast cancer | Stomach cancer | Patients | Ovarian cancer | Pancreatic cancer | PD-L1 protein | Antitumor activity | Ligands | Autoimmune diseases | Gastric cancer | Clear cell-type renal cell carcinoma | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2013, Volume 369, Issue 2, pp. 122 - 133
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2012, Volume 366, Issue 26, pp. 2443 - 2454
Releasing T cells from inhibitory control has been a strategy exploited by the anti–CTLA-4 antibody ipilimumab. Now an antibody against a second checkpoint... 
CELL LUNG-CANCER | MEDICINE, GENERAL & INTERNAL | THERAPY | SOLID TUMORS | RESPONSE CRITERIA | IMMUNOTHERAPY | GUIDELINES | B7 FAMILY | B7-H1 | ANTITUMOR IMMUNITY | BLOCKADE | Neoplasms - metabolism | Antibodies, Monoclonal - pharmacology | Humans | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - metabolism | Antibodies, Monoclonal - therapeutic use | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Melanoma - drug therapy | Adult | Female | Ligands | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Carcinoma, Renal Cell - drug therapy | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Immune response | Anti-antibodies | Dosage and administration | Product/Service Evaluations | Regulation | Research | Drug therapy | Cancer | Fees & charges | Kidneys | Stock options | PD-1 protein | Laboratories | Toxicity | Tumor cells | Body weight | Lung cancer | Colorectal carcinoma | Colorectal cancer | Melanoma | Licenses | Lymphocytes T | Patients | Castration | PD-L1 protein | Antitumor activity | Prostate cancer | Drug dosages | Prostate | Clear cell-type renal cell carcinoma | Tumors | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 10, pp. 1020 - 1030
Journal Article
Journal Article
Journal Article
by Fox, BA and Schendel, D.J and Butterfield, L.H and Aamdal, S and Allison, J.P and Ascierto, P.A and Atkins, M.B and Bartunkova, J and Bergmann, L and Berinstein, N and Bonorino, C.C and Borden, E and Bramson, J.L and Britten, C.M and Cao, X and Carson, W.E and Chang, A.E and Characiejus, D and Choudhury, A.R and Coukos, G and Gruijl, de, T.D and Dillman, R.O and Dolstra, H and noff, G and Durrant, L.G and Finke, J.H and Galon, J and Gollob, J.A and Gouttefangeas, C and Grizzi, F and Guida, M and Hakansson, L and Hege, K and Herberman, R.B and Hodi, F.S and Hoos, A and Huber, C and Hwu, P and Imai, K and Jaffee, E.M and Janetzki, S and June, C.H and Kalinski, P and Kaufmann, H.L and Kawakami, K and Kawakami, Y and Keilholtz, U and Khleif, S.N and Kiessling, R and Kotlan, B and Kroemer, G and Lapointe, R and Levitsky, H.I and Lotze, M.T and Maio, M. Di and Marschner, J.P and Mastrangelo, M.J and Masucci, G and Melero, I and Nelief, C and Murphy, W.J and Nelson, B and Nicolini, A and Nishimura, M.I and Odunsi, K and Ohashi, P.S and O'Donnell-Tormey, J and Old, L.J and Ottensmeier, C and Papamichail, M and Parmiani, G and Pawelec, G and Proietti, E and Qin, S and Rees, R and Ribas, A and Ridolfi, R and Ritter, G and Rivoltini, L and Romero, P.J and Salem, M.L and Scheper, R.J and Seliger, B and Sharma, P and Shiku, H and Singh-Jasuja, H and Song, W and Straten, P.T and Tahara, H and Tian, Z and Burg, van der, S.H and Hoegen, von, P and Wang, E and Welters, M.J and Winter, H and Withington, T and Wolchok, J.D and Xiao, W and Zitvogel, L and Zwierzina, H and ...
Journal of Translational Medicine, ISSN 1479-5876, 2011, Volume 9, Issue 1, pp. 214 - 214
Journal Article